Skip to main content
SpringerLink
Log in

Fifteen-Year Experience in Treating Blepharospasm with Botox or Dysport: Same Toxin, Two Drugs

  • Published:
Neurotoxicity Research Aims and scope Submit manuscript

Abstract

Objectives To compare the clinical characteristics and the long-term outcome of a large series of patients with blepharospasm (BS) treated with the two most used brands of BoNT-A over the last 15 years. Methods We have reviewed the clinical charts of 128 patients with BS who received botulinum neurotoxin (BoNT) in 1341 treatments (Botox in 1009, Dysport in 332) over the last 15 years. Results Mean dose per session was 34U ± 15 for Botox and 152U ± 54 for Dysport. Mean latency of clinical effect was 4.5 ± 4.6 days for Botox and 5.0 ± 5.7 days for Dysport (P > 0.05). Mean duration of clinical improvement was higher for Dysport than Botox: 80.1 ± 36.3 and 66.2 ± 39.8 days, respectively (P < 0.01). In a six-point scale (0: no efficacy, 6: remission of BS), the mean efficacy of both treatments was 3.60 ± 1.3; 3.51 ± 1.4 (Botox) and 3.85 ± 1.2 (Dysport), P < 0.01. The doses of Botox (β = 0.40) and Dysport (β = 0.16) were significantly increased over time. Side effects occurred in 325 out of 1341 treatments (24.2%): 21.8% of the patients who had received Botox, and in 31.6% of those who had received Dysport (P < 0.01). Conclusions Both brands are effective and safe in treating blepharospasm; efficacy is long lasting. The differences in outcome and side effects suggest that, albeit the active drug is the same, Botox and Dysport should be considered as two different drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

Abbreviations

BS:

Blepharospasm

BoNT:

Botulinum toxin

BoNT-A:

Botulinum toxin type A

BoNT-B:

Botulinum toxin type B

EDB:

Extensor digitorum brevis

References

  • Ainsworth JR, Kraft SP (1995) Long-term changes in duration of relief with botulinum toxin treatment of essential blepharospasm and hemifacial spasm. Ophthalmology 102:2036–2040

    PubMed  CAS  Google Scholar 

  • Albanese A, Colosimo C, Carretta D, Dickmann A, Bentivoglio AR, Tonali P (1992) Botulinum toxin as a treatment for blepharospasm, spasmodic torticollis and hemifacial spasm. Eur Neurol 32:112–117

    Article  PubMed  CAS  Google Scholar 

  • Albanese A, Barnes MP, Bhatia KP, Fernandez E, Filippini G, Gasser T, Krauss JK, Newton A, Rektor I, Savoiardo M, Valls-Solè J (2006) A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes. Report by an EFNS/MDS-ES Task Force. Eur J Neurol 13:433–444

    Article  PubMed  CAS  Google Scholar 

  • Binari K (2005) Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm. Curr Med Res Opin 21:433–438

    Article  CAS  Google Scholar 

  • Borodic GE, Ferrante R (1992) Effects of repeated botulinum toxin injections on orbicularis oculi muscle. J Clin Neuroophthalmol 12:121–127

    PubMed  CAS  Google Scholar 

  • Borodic GE, Ferrante R, Pearce LB, Smith K (1994) Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections. Mov Disord 9:31–39

    Article  PubMed  CAS  Google Scholar 

  • Brin MF, Fahn S, Moskovitz C, Friedman A, Shale HM, Greene PE, Blitzer A, List T, Lange D, Lovelace RE, McMahon D (1987) Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 2:237–254

    Article  PubMed  CAS  Google Scholar 

  • Burke RE, Fahn S, Marsden CD, Bressman SB, Moskowitz C, Friedman J (1985) Validity and reliability of a rating scale for the primary torsion dystonias. Neurology 35:73–77

    Article  PubMed  CAS  Google Scholar 

  • Burns CL, Gammon JA, Gemmill MC (1986) Ptosis associated with botulinum toxin treatment of strabismus and blepharospasm. Ophthalmology 93:1621–1627

    PubMed  CAS  Google Scholar 

  • Cakmur R, Ozturk V, Uzunel F, Donmez B, Idiman F (2002) Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neurol 249:64–68

    Article  PubMed  CAS  Google Scholar 

  • Carruthers J, Stubbs HA (1987) Botulinum toxin for benign essential blepharospasm, hemifacial spasm and age-related lower eyelid entropion. Can J Neurol Sci 14:42–45

    PubMed  CAS  Google Scholar 

  • Cohen DA, Savino PJ, Stern MB, Hurtig HI (1986) Botulinum injection therapy for blepharospasm: a review and report of 75 patients. Clin Neuropharmacol 9:415–429

    Article  PubMed  CAS  Google Scholar 

  • Costa J, Espirito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, Sampaio C (2005) Botulinum toxin type A therapy for blepharospasm. Cochrane Database Syst Rev 1:CD004900

    PubMed  Google Scholar 

  • Dressler D (2002) Dysport produces intrinsically more swallowing problems than Botox: unexpected results from a conversion factor study in cervical dystonia. J Neurol Neurosurg Psychiatry 73:604

    Article  PubMed  CAS  Google Scholar 

  • Dressler D, Hallet M (2006) Immunological aspects of Botox, Dysport and Myobloc/Neurobloc. Eur J Neurol 13(Suppl 1):S11–S15

    Article  Google Scholar 

  • Duchen LW (1971) An electron microscopic study of the changes induced by botulinum toxin in the motor end-plates of slow and fast skeletal muscle fibres of the mouse. J Neurol Sci 14:47–60

    Article  PubMed  CAS  Google Scholar 

  • Dutton JJ, Buckley EG (1988) Long-term results and complications of botulinum A toxin in the treatment of blepharospasm. Ophthalmology 95:1529–1534

    PubMed  CAS  Google Scholar 

  • Echeverria Urabayen A, Fanjul S, Meseguer E, Garcia Ruiz Espiga PJ (2004) Progression of botulinum toxin type A dosage in craniocervical dystonias. An eight year comparative study. Rev Neurol 38:511–513

    PubMed  CAS  Google Scholar 

  • Elston JS (1992) The management of blepharospasm and hemifacial spasm. J Neurol 239:5–8

    Article  PubMed  CAS  Google Scholar 

  • Elston JS, Russell RWR (1985) Effect of treatment with botulinum toxin on neurogenic blepharospasm. Br Med J 290:1857–1859

    CAS  Google Scholar 

  • Engstrom PF, Arnoult JB, Mazow ML, Prager TC, Wilkins RB, Byrd WA, Hofmann RJ (1987) Effectiveness of botulinum toxin therapy for essential blepharospasm. Ophthalmology 94:971–975

    PubMed  CAS  Google Scholar 

  • Fahn S, List T, Moskowitz C, Brin M, Bressman S, Burke R, Scott A (1985) Double-blind controlled study of botulinum toxin for blepharospasm. Neurology 35(Suppl 1):S271–S272

    Google Scholar 

  • Frueh BR, Musch DC (1986) Treatment of facial spasm with botulinum toxin: an interim report. Ophthalmology 93:917–923

    PubMed  CAS  Google Scholar 

  • Frueh BR, Felt TH, Wojno TH, Musch DC (1984) Treatment of blepharospasm with botulinum toxin: a preliminary report. Arch Ophtalmol 102:1464–1468

    CAS  Google Scholar 

  • Grandas F, Elston J, Quinn N (1988) Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry 51:767–772

    Article  PubMed  CAS  Google Scholar 

  • Hsiung GY, Das SK, Ranawaya R, Lafontaine AL, Suchowersky O (2002) Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 17:1288–1293

    Article  PubMed  Google Scholar 

  • Jankovic J, Orman J (1984) Blepharospasm: demographic and clinical survey of 250 patients. Ann Ophthalmol 16:371–376

    PubMed  CAS  Google Scholar 

  • Jankovic J, Orman J (1987) Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 37:616–623

    PubMed  CAS  Google Scholar 

  • Jankovic J, Schwartz K, Donovan DT (1990) Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry 53:633–639

    Article  PubMed  CAS  Google Scholar 

  • Kessler KR, Benecke R (1997) The EBD test—a clinical test for the detection of antibodies to botulinum toxin type A. Mov Disord 12:95–99

    Article  PubMed  CAS  Google Scholar 

  • Kraft SP, Lang AE (1988) Botulinum toxin injections in the treatment of blepharospasm, hemifacial spasm, and eyelid fasciculations. Can J Neurol Sci 15:276–280

    PubMed  CAS  Google Scholar 

  • Levy RL, Berman D, Parikh M, Miller NR (2006) Supramaximal doses of botulinum toxin for refractory blepharospasm. Ophthalmology 113:1665–1668

    Article  PubMed  Google Scholar 

  • Mauriello JA, Aijian J (1991) Natural history of treatment of facial dyskinesias with botulinum toxin: a study of 50 consecutive patients over seven years. Br J Ophthalmol 75:737–739

    Article  PubMed  CAS  Google Scholar 

  • Mauriello JA Jr, Dhillon S, Leone T, Pakeman B, Mostafavi R, Yepez MC (1996) Treatment selections of 239 patients with blepharospasm and Meige syndrome over 11 years. Br J Ophthalmol 80:1073–1076

    Article  PubMed  Google Scholar 

  • Mclellan K, Das RE, Ekong TA, Sesardic D (1996) Therapeutic botulinum type A toxin: factors affecting potency. Toxicon 34:975–985

    Article  PubMed  CAS  Google Scholar 

  • Meige H (1910) Les convulsions de la face: une forme clinique de convulsions faciales, bilaterale et mediane. Rev Neurol (Paris) 21:437–443

    Google Scholar 

  • Mejia NI, Vuong KD, Jankovic J (2005) Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord 20:592–597

    Article  PubMed  Google Scholar 

  • Naumann M, Jankovic J (2004) Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin 20:981–990

    Article  PubMed  CAS  Google Scholar 

  • Nussgens Z, Roggenkamper P (1997) Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol 235:197–199

    Article  PubMed  CAS  Google Scholar 

  • Pang AL, O’day J (2006) Use of high-dose botulinum A toxin in benign essential blepharospasm: is too high too much? Clin Experiment Ophthalmol 34:441–444

    Article  PubMed  Google Scholar 

  • Park YC, Lim JK, Lee DK, Yi SD (1993) Botulinum a toxin treatment of Hemifacial spasm and blepharospasm. J Korean Med Sci 8:334–340

    PubMed  CAS  Google Scholar 

  • Perman KI, Baylis HI, Rosenbaum AL, Kirschen DG (1986) The use of botulinum toxin in the medical management of benign essential blepharospasm. Ophthalmology 93:1–3

    PubMed  CAS  Google Scholar 

  • Ruusuvaara P, Setälä K (1990) Longterm treatment of involuntary facial spasms using botulinum toxin. Acta Ophthalmol 68:331–338

    Article  CAS  Google Scholar 

  • Sampaio C, Ferreira JJ, Simoes F, Rosas MJ, Magalhaes M, Correia AP, Bastos-Lima A, Martins R, Castro-Caldas A (1997) DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A-Dysport and Botox-assuming a ratio of 4:1. Mov Disord 12:1013–1018

    Article  PubMed  CAS  Google Scholar 

  • Sampaio C, Costa J, Ferreira JJ (2004) Clinical comparability of marketed formulations of botulinum toxin. Mov Disord 19(Suppl 8):S129–S136

    Article  PubMed  Google Scholar 

  • Scott AB (1981) Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc 79:734–770

    PubMed  CAS  Google Scholar 

  • Scott AB, Kennedy RA, Stubbs HA (1985) Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol 103:347–350

    PubMed  CAS  Google Scholar 

  • Shorr N, Seiff SR, Kopelman J (1985) The use of botulinum toxin in blepharospasm. Am J Ophthalmol 99:542–546

    PubMed  CAS  Google Scholar 

  • Silveira-Moriyama L, Goncalves LR, Chien HF, Barbosa ER (2005) Botulinum toxin a in the treatment of blepharospasm: a 10-year experience. Arq Neuropsiquiatr 63:221–224

    PubMed  Google Scholar 

  • Taylor JD, Kraft SP, Kazdan MS, Flanders M, Cadera W, Orton RB (1991) Treatment of blepharospasm and hemifacial spasm with botulinum A toxin: a Canadian multicentre study. Can J Ophthalmol 26:133–138

    PubMed  CAS  Google Scholar 

  • Thussu A, Barman CR, Prabhakar S (1999) Botulinum toxin treatment of hemifacial spasm and blepharospasm: objective response evaluation. Neurol India 47:206–209

    PubMed  CAS  Google Scholar 

  • Tsai CP, Chiu MC, Yen DJ, Guo YC, Yuan CL, Lee TC (2005) Quantitative assessment of efficacy of dysport (botulinum toxin type A) in the treatment of idiopathic blepharospasm and hemifacial spasm. Acta Neurol Taiwan 14:61–68

    PubMed  Google Scholar 

  • Van den Bergh P, Francart J, Mourin S, Kollmann P, Laterre EC (1995) Five year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin. Muscle Nerve 18:720–729

    Article  PubMed  Google Scholar 

  • Wohlfarth K, Goschel H, Frevert J, Dengler R, Bigalke H (1997) Botulinum A toxins: units versus units. Naunyn Schmiedebergs Arch Pharmacol 355:335–340

    Article  PubMed  CAS  Google Scholar 

  • Wojno T, Campbell P, Wright J (1986) Orbicularis muscle pathology after botulinum toxin injection. Ophthal Plast Reconstr Surg 2:71–74

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgement

Authors are indebted with Dr. Emanuele Cassetta, Dr Consuelo Gioia, Dr. Carlo Colosimo, who, in the past years, collected clinical data and examined patients.

This work was supported in part by Università Cattolica del Sacro Cuore, grant “linea D1” to ARB.

Author information

Authors and Affiliations

  1. Istituto di Neurologia Università Cattolica del Sacro Cuore Largo Agostino Gemelli, 8 - 00168, Rome, Italy

    A. R. Bentivoglio, A. Fasano, T. Ialongo & F. Soleti

  2. Fondazione Don Carlo Gnocchi, Rome, Italy

    A. R. Bentivoglio

  3. Istituto di Scienze Neurologiche, Università di Catania, Catania, Italy

    S. Lo Fermo

  4. Cattedra di Neurologia, Università Cattolica del Sacro Cuore, Milan, Italy

    A. Albanese

  5. Istituto Nazionale Neurologico Carlo Besta, Milan, Italy

    A. Albanese

Authors
  1. A. R. Bentivoglio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Fasano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Ialongo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Soleti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Lo Fermo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Albanese
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. R. Bentivoglio.

Additional information

ARB and AA received speaker fees and research grants from Allergan and Ipsen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bentivoglio, A.R., Fasano, A., Ialongo, T. et al. Fifteen-Year Experience in Treating Blepharospasm with Botox or Dysport: Same Toxin, Two Drugs. Neurotox Res 15, 224–231 (2009). https://doi.org/10.1007/s12640-009-9023-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12640-009-9023-3

Keywords

Search

Navigation